Smell: an extraordinarily precise sense
22 March, 2022
The two early symptoms that can reveal that you have Parkinson's
23 March, 2022
Respiratory tract infections are a major public health problem, and these development programs target the main causative agents.
Modern announced this Tuesday that it is expanding its mRNA product portfolio with two new development programs: a combined respiratory vaccine candidate (SARS-CoV-2, influenza and respiratory syncytial virus) and another against the four known endemic human coronaviruses (HCoV).
First, the vacuna to attack three of the most significant viruses that cause respiratory diseases in older adults, currently known as mRNA-1230, is planned as annual booster dose against SARS-CoV-2, flu and RSV.
Second, Moderna is launching a program to develop a candidate vaccine (mRNA-1287) against endemic human coronaviruses (HCoV). Although less known than other coronaviruses, HCoVs are an important cause of enfermedades respiratory worldwide.
Four HCoVs (HCoV-229E, -NL63, -OC43 and -HKU1) are endemic worldwide, and are responsible for approximately 10 to 30 percent of upper respiratory tract infections in adults.
Respiratory tract infections are a major public health problem, and these development programs target the main causative agents. The coronavirus, the flu seasonality and RSV have a considerable cost to the health especially among the elderly, who experience more severe illness and higher mortality than the young.
Source: Heraldo de Aragón
